EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Potential for a large‐scale newborn screening strategy for sickle cell disease in Mali: A comparative diagnostic performance study of two rapid diagnostic tests ( SickleScan ® and HemotypeSC ®) on cord blood

Aldiouma Guindo, Zenab Cisse, Ibrahima Keita, Sophie Desmonde, Yeya Dit Sadio Sarro, Boubacari A Touré, Mohamed Ag Baraika, Oumarou Tessougué, Pierre Guindo, Moussa Coulibaly, Oumar Traore, Niagalé Sylla und 5 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19108 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Aldiouma Guindo und 16 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche et Lutte contre la Drépanocytose (CRLD), Bamako, Mali. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Hemoglobin SC Disease. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fondation Pierre Fabre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sickle cell disease (SCD) is a life‐threatening disease requiring reliable early diagnosis. We assessed the acceptability and diagnostic performances of two rapid diagnostic tests (RDTs) to identify SCD (HbSS, HbSC, HbS/β‐thalassaemia) or SCD carrier (HbS/HbC) in a pilot SCD newborn screening (NBS) strategy in Mali. All consenting delivering women were offered SCD NBS using cord blood sampling on two RDTs (SickleScan® and HemotypeSC®) compared to the high‐performance liquid chromatography (HPLC) gold standard to detect SCD states. From April 2021 to August 2021, 4333 delivering women were eligible of whom 96.1% were offered NBS: 1.6% refused, 13.8% delivered before consenting and 84.6% consented; 3648 newborns were diagnosed by HPLC; 1.64% had SCD (0.63% HbSS, 0.85% HbSC, 0.16 HbS/β‐plus‐thalassaemia); 21.79% were SCD carrier. To detect accurately SCD, SickleScan® had a sensitivity of 81.67% (95% confidence interval [CI]: 71.88–91.46) and a negative predictive value (NPV) of 99.69% (95% CI: 99.51–99.87); HemotypeSC® had a sensitivity of 78.33% (95% CI: 67.91–88.76) and a NPV of 99.64% (95% CI: 99.44–99.83). To detect SCD carrier: SickleScan® sensitivity was 96.10% (95% CI: 94.75–97.45) and NPV, 98.90% (95% CI: 98.51–99.29); HemotypeSC® sensitivity was 95.22% (95% CI: 93.74–96.70) and NPV, 98.66% (95% CI: 98.24–99.03). Routine SCD NBS was acceptable. Compared with HPLC, both RDTs had reliable diagnostic performances to exclude SCD‐free newborns and to identify SCD carriers to be further confirmed. This strategy could be implemented in large‐scale NBS programmes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellHemoglobin SC DiseaseHumansInfant, NewbornFemaleNeonatal ScreeningRapid Diagnostic TestsFetal BloodMaliHemoglobin, Sickle

Stichwörter der Autor:innen

Africadiagnostic performancesnewborn screeningrapid diagnosis testsickle cell disease

Substanzen

Hemoglobin, Sickle

Autor:innen und Institutionen

  • Centre de Recherche et Lutte contre la Drépanocytose (CRLD), Bamako, Mali.
  • CERPOP, UMR 1295, INSERM, Université Toulouse 3, Toulouse, France.
  • Centre de santé de Reference de la commune 5 (CsREF-CV), Bamako, Mali.
  • Service de Gynécologie et Obstétrique, Hopital Fousseyni Daou de Kayes, Kayes, Mali.
  • Centre de santé de Reference de la commune 4 (CsREF-CIV), Bamako, Mali.
  • Fondation Mérieux, Lyon, France.

ORCID-Profile: Valériane Leroy

Förderung

  • Fondation Pierre Fabre

Zitieren

APA

Guindo, A., Cisse, Z., Keita, I., Desmonde, S., Sarro, Y. D. S., Touré, B. A., Baraika, M. A., Tessougué, O., Guindo, P., Coulibaly, M., Traore, O., Sylla, N., Diassana, M., Saye, A., Picot, V., Lauressergues, E., & Leroy, V. (2024). Potential for a large‐scale newborn screening strategy for sickle cell disease in Mali: A comparative diagnostic performance study of two rapid diagnostic tests ( SickleScan ® and HemotypeSC ®) on cord blood. British Journal of Haematology. https://doi.org/10.1111/bjh.19108

Vancouver

Guindo A, Cisse Z, Keita I, Desmonde S, Sarro YDS, Touré BA, et al. Potential for a large‐scale newborn screening strategy for sickle cell disease in Mali: A comparative diagnostic performance study of two rapid diagnostic tests ( SickleScan ® and HemotypeSC ®) on cord blood. British Journal of Haematology. 2024. doi:10.1111/bjh.19108

BibTeX
@article{Guindo2024,
  author = {Guindo, Aldiouma and Cisse, Zenab and Keita, Ibrahima and Desmonde, Sophie and Sarro, Yeya Dit Sadio and Touré, Boubacari A and Baraika, Mohamed Ag and Tessougué, Oumarou and Guindo, Pierre and Coulibaly, Moussa and Traore, Oumar and Sylla, Niagalé and Diassana, Mahamadou and Saye, Amaguiré and Picot, Valentina and Lauressergues, Emilie and Leroy, Valériane},
  title = {Potential for a large‐scale newborn screening strategy for sickle cell disease in Mali: A comparative diagnostic performance study of two rapid diagnostic tests ( SickleScan ® and HemotypeSC ®) on cord blood},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19108}
}
Kostenlos starten →